Home » Stocks » Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. (RETA)

Stock Price: $112.78 USD 3.87 (3.55%)
Updated Oct 16, 2020 4:00 PM EDT - Market closed
After-hours: $112.21 -0.57 (-0.51%) Oct 16, 7:41 PM

Stock Price Chart

Key Info

Market Cap 3.22B
Revenue (ttm) 15.34M
Net Income (ttm) -343.16M
Shares Out 28.56M
EPS (ttm) -10.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 16, 2020
Last Price $112.78
Previous Close $108.91
Change ($) 3.87
Change (%) 3.55%
Day's Open 109.93
Day's Range 107.74 - 114.69
Day's Volume 160,312
52-Week Range 88.17 - 257.97

More Stats

Market Cap 3.22B
Enterprise Value 2.61B
Earnings Date (est) Nov 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 28.56M
Float 26.68M
EPS (basic) -10.92
EPS (diluted) -10.71
FCF / Share -12.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.54M
Short Ratio 10.32
Short % of Float 13.28%
Beta 1.64
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 209.98
PB Ratio 15.80
Revenue 15.34M
Operating Income -340.97M
Net Income -343.16M
Free Cash Flow -427.78M
Net Cash 610.42M
Net Cash / Share 21.37
Gross Margin -1,644.76%
Operating Margin -2,222.89%
Profit Margin -2,237.10%
FCF Margin -2,788.85%
ROA -44.73%
ROE -346.35%
ROIC 27,134.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$236.25*
(109.48% upside)
Low
169
Current: $112.78
High
345
Target: 236.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue26.5253.5948.0649.8650.3251.95
Revenue Growth-50.52%11.51%-3.61%-0.92%-3.15%-
Gross Profit26.5253.5948.0649.8650.3251.95
Operating Income-285-76.88-46.91-6.88-0.333.63
Net Income-290-80.55-47.67-6.23-1.450.69
Shares Outstanding30.4127.7023.9319.8215.9715.95
Earnings Per Share-9.54-2.91-1.99-0.31-0.090.04
Operating Cash Flow-251-83.78-83.26-19.26-44.62-88.63
Capital Expenditures-2.67-0.68-0.34-0.34-0.26-0.14
Free Cash Flow-254-84.46-83.60-19.60-44.88-88.77
Cash & Equivalents66433813084.7373.93-
Total Debt15579.2219.61---
Net Cash / Debt50925911084.7373.93-
Assets68234513589.0978.95-
Liabilities426330282304352-
Book Value25715.16-147-215-273-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Reata Pharmaceuticals, Inc.
Country United States
Employees 220
CEO J. Warren Huff

Stock Information

Ticker Symbol RETA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RETA
IPO Date May 26, 2016

Description

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Company to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.